Cytoreason Private Financing
LOCUST WALK NEWS CytoReason secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to scale its AI disease models […]
News
News
News
Ascentage Pharma Olverembatinib
LOCUST WALK NEWS Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib Ascentage Pharma
News
Garuda Therapeutics Launches with $72 Million Series A Financing
LOCUST WALK NEWS Garuda Therapeutics Launches with $72 Million Series A Financing CAMBRIDGE, Mass.–(BUSINESS WIRE)–Garuda Therapeutics, a company creating off-the-shelf,
News
Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies
LOCUST WALK NEWS Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing
News
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies
LOCUST WALK NEWS eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company
News
Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1, 2021
LOCUST WALK NEWS Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1,
News
Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option
LOCUST WALK NEWS Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option PHILADELPHIA
Market Trends, News, Specialty pharma
RNA Therapeutics Landscape Overview
RNA Therapeutics Landscape Overview Locust Walk views RNA therapeutics in 5 key pillars: RNA Translation Inhibition Protein Expression RNA-Targeting Small
Market Trends, News, Quarterly Reports
2022 Q3 Report: Global Trends in Biopharma Transactions
2022 Q3 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
Market Trends, News
Locust Walk Breakthrough Innovation Reports: Oncology IPS-Effector Cell Therapies
Locust Walk Breakthrough Innovation Reports: Oncology IPS-Effector Cell Therapies In this report you can find an overview and analysis of